phrykt

Lyell Immunopharma, Inc. (LYEL): who owns it and who trades it

As of Nov 16, 2026, LYEL insiders reported 29 open-market sales worth $613K and 2 purchases worth $37.5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Lynn Seely (CEO), with $355K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Lyell Immunopharma

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns LYEL

87 funds and institutions reported LYEL shares worth $170M at the end of Q2 2026, about 52% of the company. The largest holder is ARCH Venture Management, LLC with 13.9%.

Funds and institutions (13F) 52%Everyone else 48%

10 largest owners, by share of the company

ARCH Venture Management, LLC13.9%
GSK plc6.5%
Vanguard Capital Management LLC3.4%
Orland Properties Ltd3.2%
BlackRock, Inc.3.1%
Almitas Capital LLC2.5%
Foresite Capital Management V, LLC2.0%
Millennium Management LLC1.6%
Opaleye Management Inc.1.5%
VenBio Partners LLC1.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
ARCH Venture Management, LLC3.25M13.93%$45.5MNo change
GSK plc1.51M6.49%$21.3MNo change
Vanguard Capital Management LLC786,7743.38%$11.1M+10%
Orland Properties Ltd754,6983.24%$10.6MNo change
BlackRock, Inc.724,3423.11%$10.2M+278%
Almitas Capital LLC581,4072.49%$8.2M+1%
Foresite Capital Management V, LLC476,3862.04%$6.7M-0%
Millennium Management LLC367,4731.58%$5.2M-20%
Opaleye Management Inc.344,0251.48%$4.8M+335%
VenBio Partners LLC337,6971.45%$4.7MNo change
Geode Capital Management, LLC310,6361.33%$4.4M+86%
Alphabet Inc.293,2561.26%$4.1MNo change
State Street Corp185,3220.80%$2.6M+156%
HSG Holding Ltd152,2990.65%$2.1MNew
Renaissance Technologies LLC130,1900.56%$1.8M+12%
Northern Trust Corp118,5000.51%$1.7M+291%
Qube Research & Technologies Ltd110,5310.47%$1.6M+101%
Charles Schwab Investment Management Inc107,5700.46%$1.5M+25%
Sixth Street Partners Management Company, L.P.107,5700.46%$1.5MNew
Marshall Wace, LLP106,3000.46%$1.5M-28%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, LYEL insiders reported $37.5M of open-market purchases and $613K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$37.5M
2 trades, 2 people
Sales, 12 months
$613K
29 trades, 7 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 12, 2026

Purchases and sales by month

$25M$25MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Veronica Sanchez BulisVice presidentSale416$15.93$6.6KForm 4
Nov 10, 2026Stephen J. HillChief Operating OfficerSale88$15.93$1.4KForm 4
Nov 10, 2026Gary K. LeeChief Scientific OfficerSale129$15.93$2.1KForm 4
Nov 10, 2026Lynn SeelyCEOSale545$15.93$8.7KForm 4
Nov 4, 2026ARCH Venture Partners IX, LLC +410% ownerPurchase2.32M$10.77$25MForm 4
Oct 12, 2026Jarrad Mattieu AguirreChief Medical OfficerSale422$8.63$3.6KForm 4
Sep 10, 2026David ShookChief Medical OfficerSale500$12.70$6.3KForm 4
Aug 21, 2026Lynn SeelyCEOSale9,589$15.54$149KForm 4
Aug 21, 2026Stephen J. HillChief Operating OfficerSale989$15.54$15.4KForm 4
Aug 21, 2026Gary K. LeeChief Scientific OfficerSale1,457$15.54$22.6KForm 4
Aug 10, 2026Veronica Sanchez BulisVice presidentSale621$14.34$8.9KForm 4
Aug 10, 2026Gary K. LeeChief Scientific OfficerSale131$14.34$1.9KForm 4
Aug 10, 2026Stephen J. HillChief Operating OfficerSale89$14.34$1.3KForm 4
Aug 10, 2026Lynn SeelyCEOSale390$14.34$5.6KForm 4
Jul 17, 2026Innovative Cellular Therapeutics Holdings Ltd10% ownerSale10$13.70$137Form 4
Jul 16, 2026Innovative Cellular Therapeutics Holdings Ltd10% ownerSale10$13.73$137Form 4
Jun 10, 2026David ShookChief Medical OfficerSale1,977$12.64$25KForm 4
May 11, 2026Lynn SeelyCEOSale388$18.91$7.3KForm 4
May 11, 2026Gary K. LeeChief Scientific OfficerSale130$18.92$2.5KForm 4
May 11, 2026Stephen J. HillChief Operating OfficerSale89$18.92$1.7KForm 4
May 11, 2026Veronica Sanchez BulisVice presidentSale217$18.91$4.1KForm 4
Mar 6, 2026ARCH Venture Partners IX Overage, L.P. +410% ownerPurchase488,090$25.61$12.5MForm 4
Feb 11, 2026Lynn SeelyCEOSale7,455$23.39$174KForm 4
Feb 11, 2026Stephen J. HillChief Operating OfficerSale1,236$23.39$28.9KForm 4
Feb 11, 2026Gary K. LeeChief Scientific OfficerSale1,671$23.39$39.1KForm 4
Feb 10, 2026Stephen J. HillChief Operating OfficerSale109$23.12$2.5KForm 4
Feb 10, 2026Gary K. LeeChief Scientific OfficerSale147$23.12$3.4KForm 4
Feb 10, 2026Lynn SeelyCEOSale438$23.12$10.1KForm 4
Feb 10, 2026Veronica Sanchez BulisVice presidentSale254$23.12$5.9KForm 4
Dec 30, 2025Veronica Sanchez BulisVice presidentSale936$32.32$30.3KForm 4
Dec 24, 2025Veronica Sanchez BulisVice presidentSale1,136$38.67$43.9KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
ARCH Venture Partners IX, LLC10% owner$25M–Nov 4, 2026
ARCH Venture Partners IX Overage, L.P.10% owner$12.5M–Mar 6, 2026
Lynn SeelyPresident and CEO, Director–$355KNov 10, 2026
Veronica Sanchez BulisVP, Corporate Controller–$99.7KNov 10, 2026
Gary K. LeeChief Scientific Officer–$71.5KNov 10, 2026
Stephen J. HillChief Operating Officer–$51.2KNov 10, 2026
David ShookChief Medical Officer–$31.3KSep 10, 2026
Jarrad Mattieu AguirreChief Medical Officer–$3.6KOct 12, 2026
Innovative Cellular Therapeutics Holdings Ltd10% owner–$274Jul 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

LYEL short interest

Moderate short interest. 5.7% of LYEL shares are sold short: about 1 share in 17. Over the last 12 reports the number of shares short went up 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.41M LYEL shares were sold short, 5.7% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 135,215 shares, buying them all back would take about 10.4 trading days (days to cover).

Shares short, % of all shares

5.73%May 15Oct 305.98%

Days to cover

10.4May 15Oct 3026.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.41M5.73%+1%135,21510.4
Oct 15, 20261.40M5.71%+11%178,1067.8
Sep 30, 20261.26M5.16%+6%170,7757.4
Sep 15, 20261.19M4.85%+5%98,36312.1
Aug 31, 20261.13M4.62%-2%127,2238.9
Aug 14, 20261.15M4.70%-6%183,8556.3
Jul 31, 20261.23M5.28%+1%142,2568.7
Jul 15, 20261.22M5.24%-0%182,2276.7
Jun 30, 20261.22M5.25%-7%355,3393.4
Jun 15, 20261.32M5.65%-3%136,9269.6
May 29, 20261.35M5.81%+1%83,48916.2
May 15, 20261.34M5.75%-0%57,65723.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Lyell Immunopharma company events

Lyell Immunopharma filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026ResultsReleased financial results. Filing
  2. Nov 4, 2026SharesSold new shares outside a public offering. Filing
  3. Sep 10, 2026AnnouncementLyell Immunopharma, Inc. issued a press release regarding the completion of the technology transfer for LYL273 to the Company’s LyFE Manufacturing Facility ™ in Bothell, Washington and an updated timeline on the Phase 1/2 trial evaluating LYL273 in metastatic colorectal cancer. Filing
  4. Aug 6, 2026ResultsReleased financial results. Filing
  5. Jun 15, 2026VoteReported shareholder vote results. Filing
  6. May 6, 2026ResultsReleased financial results. Filing
  7. Mar 12, 2026ResultsReleased financial results. Filing
  8. Mar 9, 2026LeadershipThe Board of Directors of Lyell Immunopharma, Inc. approved the appointment of Smital Shah as the Company’s Chief Financial and Business Officer and principal financial officer, effective March 9, 2026. Filing
  9. Dec 8, 2025AnnouncementLyell Immunopharma, Inc. presented at the 67 th American Society of Hematology (ASH) Annual Meeting and Exposition new clinical and translational data from its ongoing clinical trial of rondecabtagene autoleucel (ronde-cel, also known as LYL314) in patients with large B-cell lymphoma. Filing
  10. Dec 5, 2025RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Lyell Immunopharma financials

Famous investors that hold LYEL

4 of the 50 well-known investors we track reported holding LYEL in their latest 13F filing. The largest position is Jim Simons's, worth $1.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026189,122$1.9M0.0%+45%
Israel Englander · Millennium ManagementQ3 2026141,059$1.4M0.0%-62%
Ken Griffin · Citadel AdvisorsQ3 2026106,744$1M0.0%+471%
Steve Cohen · Point72 Asset ManagementQ3 202656,992$558K0.0%+119%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named LYEL in the last 120 days.

FiledHolderFormStake
Nov 10, 2026ARCH Venture Fund IX, L.P.13G/A17.4%
Nov 10, 2026ARCH Venture Fund IX, L.P.13G/A17.4%

Questions about Lyell Immunopharma, Inc. (LYEL) stock

Who owns the most LYEL stock?

The largest reported owner of Lyell Immunopharma, Inc. (LYEL) is ARCH Venture Management, LLC, with 13.9% of the company. In total, 87 funds and institutions reported holding LYEL at the end of Q2 2026, together about 52% of the shares. See the largest owners.

Are LYEL insiders buying or selling?

In the last 12 months, LYEL insiders reported 2 open-market purchases worth $37.5M and 29 sales worth $613K. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in LYEL?

As of Oct 30, 2026, 1.41M LYEL shares were sold short, 5.7% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 135,215 shares, buying them all back would take about 10.4 trading days (days to cover). See the history.

Which famous investors hold LYEL?

4 of the 50 well-known investors we track reported LYEL in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $1.9M. See all holders.

Executive pay

Lyell Immunopharma's chief executive was paid a total of $4.2M for the year ended Dec 31, 2025, up 182% from $1.5M the year before. In the last 12 months, Lyell Immunopharma's executives and directors bought no stock on the open market and sold $612K.

Chief executive, total pay$4.2MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$9.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.